| CAS NO: | 1216527-48-8 |
| 包装 | 价格(元) |
| 1mg | 电议 |
| 5mg | 电议 |
| 10mg | 电议 |
| Cas No. | 1216527-48-8 |
| 别名 | 氯诺昔康-D4,Chlortenoxicam-d4; Ro 13-9297-d4 |
| Canonical SMILES | OC(C1=C2C=C(S1)Cl)=C(C(NC3=C([2H])C([2H])=C([2H])C([2H])=N3)=O)N(C)S2(=O)=O |
| 分子式 | C13H6ClD4N3O4S2 |
| 分子量 | 375.8 |
| 溶解度 | DMSO: 2 mg/ml |
| 储存条件 | -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | Lornoxicam-d4is intended for use as an internal standard for the quantification of lornoxicam by GC- or LC-MS. Lornoxicam is a COX inhibitor and non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory and analgesic properties.1It inhibits production of thromboxane B2from arachidonic acid in HEL human erythroleukemic cells (IC50= 3 nM), which endogenously express COX-1, as well as inhibits LPS-induced formation of prostaglandin F1αfrom arachidonic acid in Mono-Mac-6 cells (IC50= 8 nM), which endogenously express COX-2. Lornoxicam reduces LPS-induced production of nitric oxide and IL-6 in cell-based assays with IC50values of 65 and 54 µM, respectively. It reduces carrageenan-induced paw edema in rats when administered intravenously at doses ranging from 0.1 to 9 mg/kg.2Formulations containing lornoxicam have been used in the management of postoperative pain. 1.Berg, J., Fellier, H., Christoph, T., et al.The analgesic NSAID lornoxicam inhibits cyclooxygenase (COX)-1/-2, inducible nitric oxide synthase (iNOS), and the formation of interleukin (IL)-6 in vitroInflamm. Res.48(7)369-379(1999) 2.Buritova, J., and Besson, J.M.Potent anti-inflammatory/analgesic effects of lornoxicam in comparison to other nsaids: A c-Fos study in the ratInflammopharmacology5(4)331-341(1997) |
m.cnreagent.com